POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental combo shows promise for Hard-to-Treat stomach cancer
Disease control OngoingThis early-phase trial tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy could help control advanced gastroesophageal cancer that cannot be surgically removed. Sixteen participants received the combination to see if it could shrink or elimin…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 10:14 UTC
-
Virus-Enhanced treatment shows promise for Hard-to-Treat esophageal cancer
Disease control OngoingThis early-phase trial studies a new treatment for people with advanced esophageal or gastroesophageal cancer who cannot have surgery. It combines a cancer-killing virus (OBP-301) with standard chemotherapy and radiation. The main goal is to check safety and find the best dose, w…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 20, 2026 11:54 UTC